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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a significant threat to human health. It is a multidrug-resistant
(MDR) pathogen capable of causing a variety of diseases. Also, MRSA is one of the most important nosocomial pathogens in burn
infection. As a treatment strategy against MRSA infections, phage therapy has the potential of becoming an alternative remedy.
Objectives: The present study aimed to isolate and characterize a lytic bacteriophage from hospital sewage to be effective against
burn wound-infecting MRSA isolates.
Methods: Staphylococcus aureus strains were isolated from hospitalized burn patients. The strains were confirmed as MRSA by the
Kirby-Bauer disk diffusion method using penicillin, methicillin, and oxacillin, as well as the PCR assay for the mecA gene. The phage
was isolated from the hospital sewage and tittered by the double layer agar (DLA) method. The spot test was used for host range
determination. The latent period and burst size were estimated from a one-step growth curve. The phage morphology was observed
by electron microscopy. The nature of the nucleic acid of the isolated bacteriophages was confirmed by Rnase A, Dnase I, and six
restriction enzymes.
Results: The titer, latent period, and burst size of the isolated phage were determined to be 1 × 109 PFU/mL, 20 min, and 190 PFU
per infected cell, respectively. It displayed a broad host range for MRSA bacteria by the spot test (27 out of 30 isolates). Electron
microscopy observation demonstrated that the phage belonged to the Myoviridea family. Digestion profiles of Rnase A, Dnase I, and
six restriction enzymes in 1% agarose gel electrophoresis showed that the genome of the isolated phage was a double-stranded DNA
with a size of < ~ 23 kbp.
Conclusions: The isolated phage (MH-1) was active against a wide range of MRSA strains recovered from burn patients. Its specificity
and remarkable lytic effects on MRSA strains emphasized that it could be a suitable candidate for use in prophylaxis and treatment
of these clinical infections.
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1. Background
The increasing appearance of multidrug-resistant
(MDR) microorganisms in clinics is a severe rising threat
to human health (1). Most recently, an estimated 2.5 mil-
lion people acquire antibiotic-resistant infections every
year in Europe and the USA leading to approximately
50,000 deaths (2). Methicillin-resistant Staphylococcus au-
reus (MRSA) is an MDR organism. It was initially detected
during the early 1960s in the United Kingdom and is now
regarded as a major hospital-acquired pathogen through-
out the world (3, 4). Methicillin-resistant S. aureus is one
of the most common nosocomial pathogens infecting
burn wounds (5). Burn patients are at an increased risk
of colonization and subsequent infections by nosocomial
pathogens due to the disruption of the skin protective bar-
rier and reduction of immune responses, which can lead
to poor clinical outcomes and increased morbidity and
mortality rates (6). There exist reports of the outbreaks
of MRSA and evidence of increasing MRSA strains in burn
units. In addition, reports indicate that burn units and
ICUs may act as reservoirs for MRSA. Despite the full com-
pliance with infection control programs, the acquisition
and transmission of MRSA are continuous problems in
burn units (7).
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Staphylococcus aureus is a common commensal bac-
terium that, as an opportunistic pathogen, is capable of
causing a variety of diseases ranging from mild skin in-
fections and food poisoning to fatal infections like endo-
carditis, pneumonia, osteomyelitis, and toxic shock syn-
drome. It is also a leading cause of infections associated
with catheters and devices (8-11). The pathogenesis of S.
aureus strains are related to the expression of different
virulence factors, including cell surface components (e.g.,
collagen-binding protein, clumping factor, fibronectin-
binding protein, and elastin binding protein) and secreted
factors (e.g., staphylokinase, toxic shock syndrome toxin-1,
hemolysin, panton-valentine leukocidin (PVL), exfoliative
toxins (eta and etb), staphylococcal enterotoxins (SEs), and
lipase) (12).
Unfortunately, MRSA is resistant to all beta-lactam
antimicrobial drugs such as penicillin, cefoxitin, and
oxacillin, except for newer cephalosporins with anti-MRSA
activity. The MRSA isolates are susceptible only to gly-
copeptides, such as vancomycin (13). In addition to
the increasing prevalence of MRSA, the emergence of
vancomycin-resistant or vancomycin-intermediate S. au-
reus (VRSA or VISA) has caused a serious problem (3, 14).
Also, community-acquired MRSA infections have increas-
ingly been identified in the past two decades (10). This mi-
croorganism has been declared as an international con-
cern by the World Health Organization (1, 15, 16). It is es-
timated that 70% of mortality in burn units is related to
infections. Thus, the management of burn patients is a
significant problem because of the outbreaks of infections
in burn units and the presence of many MDR strains. Ad-
ditionally, hospital burn units are the main reservoirs for
MRSA with the potential for rapid dissemination in the
hospital environment (17). Shahsavan et al. (5) isolated S.
aureus strains from burn patients in Tehran and reported
that most MRSA isolates were MDR and showed resistance
to β-lactams, macrolides, tetracyclines, and aminoglyco-
sides. As a result, therapeutic strategies to encounter clin-
ical infections caused by these bacteria have become lim-
ited (2). Therefore, alternative antibacterial agents and
programs must be developed (2). Moreover, due to the
rapid acquisition of resistance to new antibiotics and ris-
ing production costs, there has been little incentive to de-
velop new antibacterial agents (2, 14, 18).
Phage therapy has attracted a great deal of attention as
a strategy against MRSA infections and to provide a new
solution against the threat of MDR infections (19). This
approach uses bacterial viruses (phages) that can specifi-
cally attack pathogenic bacteria and kill them (20). Phage
therapy has the potential of being highly specific merely
against a species or even a strain responsible for infec-
tion (8, 21, 22). Moreover, their remarkable specificity pre-
vents them from affecting human cells and the composi-
tion of the body microbiota and inducing antimicrobial re-
sistance in different bacterial species (1, 22).
2. Objectives
The aim of the present study was to isolate and char-
acterize a lytic bacteriophage from hospital sewage to be
effective against burn wound-infecting MRSA isolates.
3. Methods
3.1. Isolation and Characterization of Bacterial Strains
During a nine-month period starting from September
2017 to May 2018, 30 MRSA isolates were obtained from
burn patients hospitalized at Motahari Hospital in Tehran,
Iran, and transferred to the Research Laboratory of Micro-
biology Department, Iran University of Medical Sciences.
Strains were identified as S. aureus by Gram staining, coag-
ulase, catalase, oxidase, and DNase production, as well as
mannitol fermentation and PCR amplification of the pro-
tein A gene (spa). The Kirby-Bauer disk diffusion method
was performed to confirm their resistance to penicillin,
methicillin, and oxacillin, as recommended by the Clinical
and Laboratory Standards Institute (CLSI) guidelines. Ad-
ditionally, PCR assays were carried out for the mecA gene.
After the identification of MRSA isolates, they were stored
in 20% glycerol at -20°C. Three clinical isolates (MH-1, S1,
and M2) plus a reference strain of MRSA (ATCC 43300) were
used as hosts for bacteriophage isolation and propagation
from wastewater samples.
3.2. Wastewater Sample Collection for Bacteriophage Isolation
Several wastewater samples were taken from un-
treated sewage ponds of Motahari Hospital and screened
as sources of bacteriophages. The samples were cen-
trifuged at 2,500 × g for 20 min to separate bacterial cells
and debris. The supernatant was filtered through 0.45 µm
filters, transferred to a clean tube, and stored at 4°C (23).
3.3. Isolation and Purification of Bacteriophages
For phage isolation, 10 mL of exponential phase cul-
ture of clinical and standard strains of S. aureus was mixed
with 10 mL of fresh LB broth (2X) and 10 mL of filtered
sewage sample, and incubated overnight at 37°C with shak-
ing at 80 rpm. The culture was then centrifuged for 20
min at 2,500 × g to remove bacteria and the supernatant
was filtered through 0.22µm pore size Millipore filters (for
phage amplification, the simultaneous culturing step was
repeated three or more times). This lysate (supernatant)
was examined for lytic phage in the plaque assay by the
Double-layer Agar (DLA) method (23).
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3.4. Double Layer Agar
In this method, one milliliter of phage lysate was
mixed with 500 µL of a stationary phase culture of host
S. aureus. After 10 min incubation at 37°C, 5 mL of LB top
agar (4 mM CaCl2, 4 mM MgSO4, 0.7% (w/v) agar, at 45°C)
was added, mixed, and overlaid onto fresh LB agar plates
(1.5% (w/v) agar) prepared before. After solidifying, the
plates were incubated overnight at 37°C until lysis zones
appeared (24).
3.5. Purification of Bacteriophage
Single plaques from each plate were picked by a ster-
ile Pasteur pipette and placed in a tube containing one
milliliter of LB broth (45°C). One milliliter of stationary
phase culture of host bacteria was added to each tube and
incubated for 24 h at 37°C and 80 rpm. On the next day,
the lysate was screened for the presence of plaques as de-
scribed above. Purification was carried out by three serial
single-plaque isolations (25).
3.6. Determination of Bacteriophage Titer
Ten sterile tubes containing 900 µL Luria Bertani (LB)
broth were numbered from 10-1 to 10-10. Next, 100 µL of
phage lysate was added to the first tube (10-1), mixed well,
and then 100 µL was transferred to the second tube (10-2)
in series (10-1 to 10-10). The same pattern was used to make
serial dilutions. Then, 100 µL of an exponential phase cul-
ture of host MRSA was added to each tube and mixed with
100 µL of each dilution of phage lysate (10-5 to 10-9). Tubes
were incubated for 10 min at 37°C for phage adsorption.
Five tubes containing 3 mL of LB soft agar (0.4% agar, 4
to 10 mM CaCl2, and MgSO4) at 45°C were numbered from
10-5 to 10-9. The phage and bacterial suspensions were
added to soft agar tubes and after mixing were overlaid
onto plates containing LB agar (1.5% agar). Plates were in-
cubated overnight at 37°C and the resulting plaques were
counted. In this way, PFU/mL was equal to the number of
plaques/dilution× volume of diluted phage added to each
plate (26).
3.7. Host Range Determination
Thirty MRSA clinical isolates, recovered from burn pa-
tients, were used to determine the host range of the iso-
lated bacteriophage. To determine the susceptibility of
methicillin-susceptible S. aureus (MSSA) strains to phage-
mediated lysis, 30 of its strains from burn patients were
also examined. Bacterial strain susceptibilities were de-
tected by the spot test method described by Kutter with
some modifications (24). Briefly, bacterial strains were in-
cubated for 4 h in LB broth at 37°C and 180 rpm (OD 600
nm= 0.4 - 0.6). Then, 500 µL of each bacterial culture was
added to 6 mL of 0.4% LB soft agar (45°C) and poured onto
LB agar plates. The plates were left to dry for 10 min. Subse-
quently, 10 µL of the phage lysate (109 PFU/mL) was spot-
ted on lawns of different bacterial strains and incubated
overnight at 37°C for the formation of a lysis zone. Lytic ac-
tivity of the isolated phage was also examined on Staphy-
lococcus epidermidis, Enterococcus faecalis, and Enterococcus
faecium strains.
3.8. Electron Microscopy
In this method, 10 µL of polyethylene glycol precipi-
tated phage particles were spotted onto a carbon-coated
copper acid grid for 3 - 5 min and then blotted with a fil-
ter paper and stained with 1% (w/v) uranyl acetate (pH = 7).
It was examined by a Zeiss LEO 906 transmission electron
microscope (Carl Zeiss LEO EM 906 E, Germany) at an accel-
erating voltage of 100 kV (26).
3.9. Naming the Isolated Bacteriophage
We named one of our isolated phages as vB-StuM-MH-
1 according to the newly proposed naming system vB-
StuP/M/S MHno, where vB refers to bacterial virus, Stu is
an abbreviation for genus/species of the host, P refers to
podovirus, M to myovirus, S to siphovirus, and MHno to the
name and number of the phage. The last part of the name
(MH-1) is the phage’s common name (27).
3.10. One-Step Growth Curve
One-step growth experiments were performed using a
method described by Wang et al. (28) with some modifica-
tions. Briefly, a mid-exponential-phase culture (30 mL) of
S. aureus (OD600nm = 0.4 to 0.5) was harvested by centrifu-
gation and re-suspended in 7.5 mL of fresh LB broth. Phage
lysates (109 PFU/mL) were added at an MOI of 0.0005 and
incubated at 37°C for 15 min for phage adsorption. The mix-
ture was then centrifuged at 10,000 × g for 10 min to re-
move free phage particles. The pellet was re-suspended in
10 mL of LB broth and incubated at 37°C. Samples were re-
moved at 10-min intervals for 2 h. The samples were imme-
diately diluted 10-fold and plated for phage titration using
the DLA method. On the next day, plaques were counted
and PFU/mL was calculated as mentioned above.
3.11. Isolation of Bacteriophage Genome
The extraction of phage genomic DNA was done ac-
cording to the Martha and Clokie method with slight mod-
ification (26). Briefly, 10 mL of phage lysates (with 10%
PEG 8000, and 1 M concentration of NaCl) were incubated
overnight at 4°C and centrifuged at 10,000 × g for 15 min.
The pellets were re-suspended in 500 ml of SM buffer and
transferred to a 2-mL Eppendorf tube. A mixture of 5µL of 1
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mg/ml DNase I and 2 µL of 12.5 mg/mL RNase A were added
to the tube and incubated for 30 min at 37°C. Afterward,
12 µL of 20% SDS and 5 µL of 10 mg/mL proteinase K were
added to the mixture and incubated for 30 min at 37°C.
Extraction was carried out with 0.5 mL of phenol: chloro-
form: isoamyl alcohol (25:24:1) solution. The mixture was
spun for 5 min at 15,000 × g for phase separation. The su-
pernatant was transferred into a fresh tube and extracted
once with 0.5 ml of chloroform: isoamyl alcohol (24:1) so-
lution, followed by centrifugation for 5 min at 8,000 × g.
The supernatant was transferred into a fresh 2-mL Eppen-
dorf tube and 500 µL of 100% isopropanol and 45 µL of
3 M sodium acetate (pH = 5.2) were added. The DNA was
left for 30 min to precipitate at room temperature. Fol-
lowing centrifugation for 20 min at 14,000 × g, the DNA
pellet was washed twice with 70% ethanol and left to dry.
The dried DNA pellet was re-suspended in 50µL of distilled
water. The phage genomic DNA concentration and qual-
ity were determined using a NanoDrop spectrophotome-
ter (Nanodrop One C, Thermo Fisher Scientific, assembled
in USA), following the instructions provided by the man-
ufacturer. Then, 10 µL of genomic DNA was resolved by
electrophoresis on the 0.1% agarose gel with DNA molecu-
lar weight marker (λ-Hind III digest) and D2000 DNA size
marker (Takara).
3.12. Restriction Digestion of Phage DNA
The DNA of the isolated bacteriophage was digested for
5 - 16 h using Rnase A, Dnase I, and six restriction endonu-
cleases (EcoRV, EcoRI, HaeIII, XbaI, SmaI, SacII, and EcoRV)
purchased from Thermo scientific (EU), Lithuania. After
the enzymatic digestion, restriction fragments were sep-
arated by electrophoresis on a 1% agarose gel containing
safe stain (SMO Bio-FluoroVue Nucleic Acid Gel Stain (pre-
stain)) in TBE buffer (Tris-boric acid-EDTA), at 90 V in a peQ
Lab agarose gel electrophoresis system (peQLAB, E0303, Tai-
wan). Gene ruler 10 Kb DNA ladder (Thermo Fisher scien-
tific) was used as a size marker. The gel was visualized in a
gel documentation system (Vilber Lourmat, E-Box CX5.TS,
France). Restriction digestions were performed in tripli-
cate.
3.13. Bacteriophage Storage
Phage lysate was filtered and precipitated by adding
polyethylene glycol 8,000 (BIO BASIC Canada INC. Cat. #:
PB0433) and NaCl (Merck, EMSURE® ACS, ISO, Reag. Ph Eur,
Germany) to final concentrations of 10% and 1 M, respec-
tively, followed by incubation at 4°C for 18 h. The lysate was
centrifuged at 10,000× g for 20 min. The phage pellet was
re-suspended in SM buffer (100 mM NaCl, 10 mM MgSO4, 10
mM Tris-HCl [pH = 7.5]) with 50% (v/v) glycerol and stored at
80°C for long-term use. For short-term use, prepared stocks
were stored at 4°C.
4. Results
4.1. Bacteriophage Isolation
A total of six phages were isolated. Phage MH-1 was
chosen for host range determination and continuing the
study.
4.2. Host Range Analysis
Of the 30 MRSA and 30 MSSA isolates, 27 strains (90%)
and 26 strains (86.6%) were sensitive to the isolated phage,
respectively, and formed the zone of lysis in the spot test
(Figure 1). The lytic activity of the isolated phage was also
examined on three other bacterial species. All of the S. epi-
dermidis, E. faecalis, and E. faecium strains were found to be
resistant to our isolated phage (Table 1).
Figure 1. Spot test
4.3. Morphology of the Lytic Bacteriophage
The designation of morphological characteristics by
electron microscopy revealed that this phage was a mem-
ber of the Myoviridea family with a contractile, long, and
relatively thick tail and isomeric large head with about 220
and 100 nm in diameter, respectively (Figure 2).
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Figure 2. The TEM image of phage MH-1 belonging to the Myoviridea family. A indicates the non-contracted and B contracted tails, respectively. The phages were negatively
stained with 1% (wt/v) uranyl acetate and observed using a Zeiss LEO 906 transmission electron microscope (Carl Zeiss LEO EM 906 E, Germany) at an accelerating voltage of
100 kV.








MRSA 30 27 out of 30 Clinical isolates
(burn patients)
MSSA 30 26 out of 30 Clinical isolates
(burn patients)
S. epidermidis 30 Not susceptible
to phage MH-1
Clinical isolates
E. faecalis 6 Not susceptible
to phage MH-1
Clinical isolates
E. faecium 30 Not susceptible
to phage MH-1
Clinical isolates
4.4. Determination of Bacteriophage Titer
The phage titer was ascertained by the serial dilution
and DLA method. Plaques were counted after overnight in-
cubation at 37°C and the titer of the isolated phage was de-
termined to be 1 × 109 PFU/ml (Figure 3).
4.5. Latent Time and Phage Burst Size
To determine the latent time and burst size of the
phage MH-1, a one-step growth curve analysis was per-
formed. From the analysis of the MH-1 one-step growth
curve, the latent period was estimated to be about 20 min.
The burst size was 190 PFU per infected cell (Figure 4).
4.6. Isolation of Genomic DNA of Bacteriophages
The genomic DNA of phage MH-1 was < ~ 23 kbp and
it was totally digested by DNase I but not by RNase A (Fig-
ure 5). The EcoRI, HaeIII, XbaI, SacII, and EcoRV restric-
tion enzymes digested the phage DNA. However, the phage
Figure 3. The titer of bacteriophage MH-1 assessed with DLA method
genome seemed to be resistant to digestion by the SmaI re-
striction enzyme (Figure 6).
5. Discussion
Treatment of staphylococcal infections is becoming in-
creasingly difficult in view of the widespread presence of
MRSA in burn wards (7). Therefore, the necessity for an al-
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Figure 4. One-step growth curves of isolated phage. L, latent time; B, burst size.
Figure 5. Agarose gel electrophoresis of MH-1 phage genomic DNA. It was treated
with Rnase A and Dnase I. Lane M1, λ-Hind III digest DNA size marker; lane 1, un-
treated DNA; lane 2, Dnase I digested DNA; lane 3, Rnase A treated DNA; Lane M2,
D2000 size marker.
ternative therapeutic method other than antibiotics seems
absolutely crucial. Our study highlights the bacteriophage
use as a possible alternative solution. Phage MH-1 showed
broad lytic activities (90%) and promising potential for
phage therapy.
A few studies are available concerning MRSA bacterio-
phages in Tehran, Iran, and there is limited information
about these local phages and their therapeutic potential.
Therefore, in the current study, we carried out a study for
the isolation of new staphylococcal bacteriophages that
would be specifically active against MRSA strains isolated
Figure 6. DNA restriction endonuclease digestion of MH-1 from the Myoviridae fam-
ily. Lane M, 10 Kb DNA size marker; lane 1, not digested DNA; lane 2, EcoRV; lane 3,
EcoR; lane 4, XbaI; lane 5: HaeIII; lane 6, SacII; lane 7, SmaI.
from burn patients. In the first step, a total of 30 MRSA
isolates were collected to be used as hosts. Further char-
acterization was carried out to confirm that the bacteria
were S. aureus as expected and to ascertain their resistance
to methicillin. Bacteriophage screening, the evaluation of
their lytic abilities, and host range determination were the
next steps. In the present study, we successfully isolated
six virulent phages against MRSA from Motahari hospital
sewage over the course of six months. In various studies,
such as our study, wastewater has been used as a phage
isolation reservoir (29-33). The MH-1 titer was determined
to be 1 × 109 PFU/mL; therefore, hospital sewage seems to
be a good source for the isolation of this phage. This sug-
gests that potentially valuable therapeutic phages can be
easily recovered from such sources and wastewater may
have diverse phage populations that could be used for a
wide range of applications. Many phages form transparent
plaques and are typical of lytic (virulent) phages, whereas
phages with the ability to lysogenize host cells (temperate
phages) produce opaque plaques. Some phages produce
halo plaques, meaning they have semi-transparent areas
around the plaques. Halos are due to the release and sub-
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sequent activity of soluble enzymes produced by a phage
that degrade the cell wall (34). After 18 h incubation at 37°C,
the MH-1 phage produced clear plaques without halo with
0.5 - 2 mm in diameter, which is further indicative of the
strict lytic nature of the isolated phage.
Phages can detect bacterial cell surface components in-
cluding lipopolysaccharide (LPS), peptidoglycan, teichoic
acids, outer membrane proteins, oligosaccharides, cap-
sules, and type IV fimbria for the binding process. The
specificity of the interaction between phage surface struc-
tures and host cell surface receptors is more influential on
the bacterial host phage range (35-39). In this study, MH-1
showed broad lytic activities on the tested MRSA and MSSA
strains collected from burn patients. Most of our S. aureus
strains (53 of 60 strains) were lysed by the isolated phage
but no plaque production was observed in the examined
S. epidermidis, E. faecalis, and E. faecium strains. This re-
sult suggests that the isolated phage was completely spe-
cific for S. aureus but there was no difference in suscepti-
bility to the isolated phage between methicillin-resistant
and methicillin-sensitive strains. Thus, the MH-1 phage can
be used as a disinfectant for circulating S. aureus strains in
burn care units and prevent the spread of bacteria and an-
tibiotic resistance.
Morphological characteristics of phages can be used
for their classification. While there is a variety of differ-
ent morphological phage types, most S. aureus phages pos-
sess icosahedral capsids whit double-stranded (ds) DNA
as a genome and belong to the caudovirales order (tailed
phages). This order is further classified based on the
tail morphology into three major families: Podoviridae
(characterized by short non-contractile tails), Myoviridea
(equipped with long contractile tails), and Siphoviridae
(with long, flexible, non-contractile tails) (40, 41). Elec-
tron microscopy observation of phage MH-1 revealed that
this phage belonged to the Myoviridea family. Phages from
the Myoviridea family have double-layered contractile tails
composed of an inner tube covered by an outer sheath and
ended by a base plate (Figure 2). The outer sheath con-
traction of the tail pushes the tube through the bacterial
cell wall and creates a channel for the viral genome deliv-
ery into the host cell’s cytoplasm (42). There are reports
of other studies that have isolated myophages for Staphy-
lococcus aureus (8, 43).
The one-step growth curve was determined to under-
stand the growth of the phage in S. aureus ATCC 43300 as a
host. The isolated phage had a short latent period (20 min)
and a large burst size (190 PFU/cell). The short latent time
showed that the time needed to replicate the virus inside
the host is very short and a new generation of phage will
be propagated after 20 min. This feature shows a high ther-
apeutic potential for this phage. Moreover, the brut size
of this phage could be of relevant interest because it pro-
vides high concentrations needed for phage therapy with
little propagation. All of these properties make the MH-1
phage a suitable candidate for biocontrol of this resistant
bacterium.
The digestion of DNA with DNase I, but not with
RNase A, evidenced that the isolated phage had the ds
DNA, as expected. To confirm this result, the extracted
genome of the phage was digested with six restriction en-
zymes. The isolated phage DNA samples were sensitive
to EcoRV, EcoRI, XbaI, and HaeIII, and exhibited different
restriction endonuclease patterns. Additionally, it seems
that the genomic DNA of the isolated phage lacked tar-
get sequences recognized by the SmaI restriction enzyme.
Phages have developed different anti-restriction strategies
against restriction-modification systems (R-M) of bacteria.
This system operates a defense against phage infections
by means of endonuclease and methyltransferase enzymes
(44). The R-M system protects methylated bacterial DNA
and cuts off the foreign unmethylated DNA in the identi-
cal sequence. If oligonucleotide recognition sequences are
present, an unmodified DNA molecule will be hydrolyzed
by restriction endonucleases. Point mutations or acquisi-
tions of the cognate methylase gene are the strategies used
by bacteriophages to change endonuclease recognition se-
quences in their genomes (44). However, for the exact de-
termination of recognition sequences in the DNA of phage
MH-1, complete genome sequencing is required.
In this study, phage MH-1 was isolated and character-
ized as a new biological strategy to prevent MRSA infection
in burn patients. Its specificity, remarkable lytic effect, and
broad-host-range for MRSA strains emphasized that it has
a considerable potential to use for prophylaxis and treat-
ment of staphylococcal infections. Because of these fea-
tures, the MH-1 phage can also be used as a component of
anti-staphylococcal and other antibacterial cocktails. It is
obvious that additional studies are required to identify the
lytic effect of this phage on MRSA isolates from different
sources. Additionally, in vivo studies on experimentally in-
duced animal or human infections should be carried out
to fully ascertain the phage therapeutic potentials.
5.1. Conclusions
The isolation of specific lytic phages to use against
multidrug-resistant Staphylococcus aureus, especially in
burn patients, can be promising for the treatment of MRSA
infections in the future. In addition, given the cost im-
posed by mortality and morbidity due to the widespread
presence of multidrug-resistant S. aureus strains and the
lack of an effective solution to this problem, the evalua-
tion of phage therapeutics in human disease management
seems to be a reasonable proposition. As a result, phage
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therapy can be an alternative to antibiotics to replace them
when they fail. This treatment may help prevent poten-
tially fatal infections in the hospital setting. Moreover, the
substantially lower cost of phage therapy is another impor-
tant reason for its broader consideration in the current pe-
riod of the global crisis in antibiotic resistance and health
care economy.
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